Cellular senescence in naevi and immortalisation in melanoma: A role for p16?

British Journal of Cancer

Volumn 95, Issue 4, 2006, Pages 496-505

  Gray Schopfer, V C ^a,b   Cheong, S C ^a,f   Chong, H ^a   Chow, J ^a   Moss, T ^c   Abdel Malek, Z A ^d   Marais, R ^b   Wynford Thomas, D ^e   Bennett, D C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

Author keywords

Cellular senescence; Immortalisation; Melanoma; Naevus; p16; p53

Indexed keywords

PROTEIN P16; PROTEIN P21; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CELL DIVISION; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOCYTIC NEVUS; MELANOMA; NEVUS; PRIORITY JOURNAL; SOMATIC CELL; TUMOR SUPPRESSOR GENE;

CELL AGING; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; HUMANS; MELANOCYTES; MELANOMA; NEVUS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747192833     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603283     Document Type: Article

References (54)

1. Bandyopadhyay D, Timchenko N, Suwa T, Hornsby PJ, Campisi J, Medrano EE (2001) The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells. Exp Gerontol 36: 1265-1275
2. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475-5483
3. Bastian BC (2003) The longer your telomeres, the larger your nevus? Am J Dermatopathol 25: 83-84
4. Bennett DC (2003) Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22: 3063-3069
5. Bennett DC (2006) Familial melanoma genes, melanocyte immortalization and melanoma initiation. In: Melanocytes to Melanoma: The Progression to Malignancy, Hearing VJ, Leong SPL (eds) New Jersey: Humana Press
6. Bennett DC, Bridges K, McKay IA (1985) Clonal separation of mature melanocytes from premelanocytes in a diploid human cell strain: spontaneous and induced pigmentation of premelanocytes. J Cell Sci 77: 167-183
7. Bennett DC, Medrano EE (2002) Molecular regulation of melanocyte senescence. Pigment Cell Res 15: 242-250
8. Bodnar AG, Quellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtensteiner S, Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352
9. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665
10. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37: 745-749
11. Clark WH (1991) Tumour progression and the nature of cancer. Br J Cancer 64: 631-644
12. Clark WH, Elder DE, Guerry D, Epstein MN, Greeve MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15: 1147-1165
13. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M (2005) Tumour biology: senescence in premalignant tumours. Nature 436: 642
14. Collado M, Serrano M (2006) The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472-476
15. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147
16. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198
17. Danos O, Mulligan RC (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85: 6460-6464
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
19. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367
20. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR (2006) COSMIC 2005. Br J Cancer 94: 318-322
21. Gilchrest BA, Treloar V, Grassi AM, Yaar M, Szabø G, Flynn E (1986) Characteristics of cultivated adult human nevocellular nevus cells. J Invest Dermatol 87: 102-107
22. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W (1999) Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291: 81-87
23. Gray-Schopfer VC, Bennett DC (2006) The genetics of melanoma. In: The Pigmentary System. Physiology and Pathophysiology, Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP (eds) New York: Oxford University Press
24. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10: 351-353
25. Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB (1986) Human melanocytes cultured from nevi and melanomas. J Invest Dermatol 87: 95-101
26. Halbert CL, Demers GW, Galloway DA (1991) The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65: 473-478
27. Hayward NK (2003) Genetics of melanoma predisposition. Oncogene 22: 3053-3062
28. Healy E, Belgaid C, Takata M, Harrison D, Zhu NW, Burd DA, Rigby HS, Matthews JN, Rees JL (1998) Prognostic significance of allelic losses in primary melanoma. Oncogene 16: 2213-2218
29. Herlyn M, Balaban G, Bennicelli J, Guerry D, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell PC, Clark WH, Koprowski H (1985) Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74: 283-289
30. Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, Newton-Bishop J, Peters G (2002) Biallelic mutations in p16INK4a confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 22: 8135-8143
31. Hussein MR, Wood GS (2002) Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn 4: 71-80
32. Kefford RF, Mann GJ, Newton Bishop J (2004) Genetic predisposition to melanoma. In: Textbook of Melanoma, Thompson JF, Morton DL, Kroon BBR (eds) pp 56-64. New York: Martin Dunitz
33. Keller-Melchior R, Schmidt R, Piepkorn M (1998) Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 110: 932-938
34. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ (1998) Both RB/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88
35. Kurz DJ, Decary S, Hong Y, Erusalimsky JD (2000) Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113(Part 20): 3613-3622
36. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724
37. Minwalla L, Zhao Y, Le Poole IC, Wickett RR, Boissy RE (2001) Keratinocytes play a role in regulating distribution patterns of recipient melanosomes in vitro. J Invest Dermatol 117: 341-347
38. Mooi WJ (1997) The dysplastic naevus. J Clin Pathol 50: 711-715
39. Mooi WJ, Peeper DS (2002) Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathol 41(Suppl 2): 120-146
40. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716
41. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20
42. Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW, Wright WE (2001) Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 15: 398-403
43. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186
44. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, Majewski S, Krupp G, Jablonska S, Parwaresch R (2000) Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol 156: 1425-1432
45. Scott MC, Wakamatsu K, Ito S, Kadekaro AL, Kobayashi N, Groden J, Kavanagh R, Takakuwa T, Virador V, Hearing VJ, Abdel-Malek ZA (2002) Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 115: 2349-2355
46. Sharpless NE, DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113: 160-168
47. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nature Rev Mol Cell Biol 2: 731-737
48. Stewart SA, Ben Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA (2003) Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 33: 492-496
49. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA (2002) Significant impact of promoter hypermethylation and the 540 C4T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161: 229-237
50. Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D, Wynford-Thomas D, Bennett DC (2003) p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 95: 723-732
51. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T (1997) Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74: 255-259
52. Von Zglinicki T, Saretzki G, Ladhoff J, d'Adda dF, Jackson SP (2005) Human cell senescence as a DNA damage response. Mech Ageing Dev 126: 111-117
53. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338-2342
54. Wynford-Thomas D (1999) Cellular senescence and cancer. J Pathol 187: 100-111